Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 3—March 2025
Dispatch
Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA
Figure

Figure. Monthly testing volumes and rates of MRMp infections among children after COVID-19 pandemic, Ohio, USA. Samples were tested for Mycoplasma pneumoniae infection during September 2023–September 2024 by FilmArray Respiratory Panel version 2.1 (BioFire Diagnostics, https://www.biofiredx.com), an in-house M. pneumonia PCR, or both. Macrolide resistance was determined in a subset of samples. MRMp rates were not available during September 2023–December 2023. MRMp, macrolide-resistant Mycoplasma pneumoniae.
Page created: January 15, 2025
Page updated: February 21, 2025
Page reviewed: February 21, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.